Long-term follow-up for young women after a heart attack
WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction in France: Clinical, Morphological and Biological Descriptive Analysis: Cohort Follow up
This follow-up will see if tracking health outcomes, quality of life, and mental health over time helps understand risks for women who had a heart attack before age 50.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 314 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | Female |
| Sponsor | French Cardiology Society Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT07181317 on ClinicalTrials.gov |
What this trial studies
The original WAMIF cohort enrolled 314 women under age 50 with acute myocardial infarction across 30 French centers from 2017–2019 and collected clinical, morphological, and biological data through 12 months. This extension continues observational follow-up beyond 12 months and captures major cardiovascular events along with standardized patient questionnaires on quality of life and mental health. No new treatments are given; data collection relies on medical records, event reporting, and patient-reported outcome measures. The extended data set will characterize long-term outcomes, recurrent events, and persistent modifiable risk factors in this young female MI population.
Who should consider this trial
Good fit: Women who originally participated in the WAMIF cohort (registration 2015-A01263-46 / NCT03073447), had an MI before age 50, and consent to continued follow-up are eligible.
Not a fit: People who did not take part in the original WAMIF cohort or those with life-limiting non-cardiac conditions are unlikely to gain benefit from this extended cardiac follow-up.
Why it matters
Potential benefit: If successful, the findings could help clinicians tailor long-term follow-up and prevention for women who have an MI at a young age.
How similar studies have performed: Other observational cohort follow-ups in young MI populations have provided useful long-term outcome and risk-factor data, but extended follow-up in this specific French WAMIF cohort is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
All patients who participated in the WAMIF study (research registration number with the French Ministry of Health : 2015-A01263-46 / Protocol registration with Clinical Trials NCT03073447) and wish to continue follow-up in the study.
Where this trial is running
Paris
- Hôpital de la Pitié Salpétrière — Paris, France (Recruiting)
Study contacts
- Principal investigator: Stéphane MANZO SILBERMAN, MD — Hôpital de la Pitié-Salpêtrière, APHP
- Study coordinator: Tessa BERGOT, MSc
- Email: tessa.bergot@sfcardio.fr
- Phone: +33144907033
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.